Tacforius

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
10-01-2023
Ciri produk Ciri produk (SPC)
10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
26-01-2018

Bahan aktif:

tacrolimus monohydrate

Boleh didapati daripada:

Teva B.V.

Kod ATC:

L04AD02

INN (Nama Antarabangsa):

tacrolimus

Kumpulan terapeutik:

Immunosuppressants

Kawasan terapeutik:

Liver Transplantation; Kidney Transplantation

Tanda-tanda terapeutik:

Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

Ringkasan produk:

Revision: 7

Status kebenaran:

Authorised

Tarikh kebenaran:

2017-12-08

Risalah maklumat

                                51
B. PACKAGE LEAFLET
52
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TACFORIUS 0.5 MG PROLONGED-RELEASE HARD CAPSULES
TACFORIUS 1 MG PROLONGED-RELEASE HARD CAPSULES
TACFORIUS 3 MG PROLONGED-RELEASE HARD CAPSULES
TACFORIUS 5 MG PROLONGED-RELEASE HARD CAPSULES
tacrolimus
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs and illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Tacforius is and what it is used for
2.
What you need to know before you take Tacforius
3.
How to take Tacforius
4.
Possible side effects
5.
How to store Tacforius
6.
Contents of the pack and other information
1.
WHAT TACFORIUS IS AND WHAT IT IS USED FOR
Tacforius contains the active substance tacrolimus. It is an
immunosuppressant. Following your organ
transplant (liver, kidney), your body’s immune system will try to
reject the new organ. Tacforius is
used to control your body’s immune response, enabling your body to
accept the transplanted organ.
You may also be given Tacforius for an ongoing rejection of your
transplanted liver, kidney, heart or
other organ when any previous treatment you were taking was unable to
control this immune response
after your transplantation.
Tacforius is used in adults.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE TACFORIUS
_ _
DO NOT TAKE TACFORIUS_ _
-
if you are allergic to tacrolimus or any of the other ingredients of
this medicine (listed in
section 6).
-
if you are allergic to sirolimus or to any macrolide-antibiotic (e.g.,
erythromycin,
clarithromycin, josamycin).
WARNINGS AND PRECAUTIONS
Tacrolimus immediate release capsules (e.g, Tacni) and 
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Tacforius 0.5 mg prolonged-release hard capsules
Tacforius 1 mg prolonged-release hard capsules
Tacforius 3 mg prolonged-release hard capsules
Tacforius 5 mg prolonged-release hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Tacforius 0.5 mg prolonged-release hard capsules
Each prolonged-release hard capsule contains 0.5 mg tacrolimus (as
monohydrate).
_Excipient with known effect _
Each capsule contains 53.725 mg lactose.
Tacforius 1 mg prolonged-release hard capsules
Each prolonged-release hard capsule contains 1 mg tacrolimus (as
monohydrate).
_Excipient with known effect _
Each capsule contains 107.45 mg lactose.
Tacforius 3 mg prolonged-release hard capsules
Each prolonged-release hard capsule contains 3 mg tacrolimus (as
monohydrate).
_Excipient with known effect _
Each capsule contains 322.35 mg lactose.
Tacforius 5 mg prolonged-release hard capsules
Each prolonged-release hard capsule contains 5 mg tacrolimus (as
monohydrate).
_Excipients with known effect _
Each capsule contains 537.25 mg lactose and 0.0154 mg ponceau 4R.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Prolonged-release hard capsule (prolonged-release capsule)
Tacforius 0.5 mg prolonged-release hard capsules
Gelatin capsules imprinted with “TR” on the light yellow capsule
cap and “0.5 mg” on the light orange
capsule body.
Tacforius 1 mg prolonged-release hard capsules
Gelatin capsules imprinted with “TR” on the white capsule cap and
“1 mg” on the light orange capsule
body.
3
Tacforius 3 mg prolonged-release hard capsules
Gelatin capsules imprinted with “TR” on the light orange capsule
cap and “3 mg” on the light orange
capsule body.
Tacforius 5 mg prolonged-release hard capsules
Gelatin capsules imprinted with “TR” on the greyish red capsule
cap and “5 mg” on the light orange
capsule body.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Prophylaxis of transplant rejection in adult kidney or
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 10-01-2023
Ciri produk Ciri produk Bulgaria 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 26-01-2018
Risalah maklumat Risalah maklumat Sepanyol 10-01-2023
Ciri produk Ciri produk Sepanyol 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 26-01-2018
Risalah maklumat Risalah maklumat Czech 10-01-2023
Ciri produk Ciri produk Czech 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 26-01-2018
Risalah maklumat Risalah maklumat Denmark 10-01-2023
Ciri produk Ciri produk Denmark 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 26-01-2018
Risalah maklumat Risalah maklumat Jerman 10-01-2023
Ciri produk Ciri produk Jerman 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 26-01-2018
Risalah maklumat Risalah maklumat Estonia 10-01-2023
Ciri produk Ciri produk Estonia 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 26-01-2018
Risalah maklumat Risalah maklumat Greek 10-01-2023
Ciri produk Ciri produk Greek 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 26-01-2018
Risalah maklumat Risalah maklumat Perancis 10-01-2023
Ciri produk Ciri produk Perancis 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 26-01-2018
Risalah maklumat Risalah maklumat Itali 10-01-2023
Ciri produk Ciri produk Itali 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 26-01-2018
Risalah maklumat Risalah maklumat Latvia 10-01-2023
Ciri produk Ciri produk Latvia 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 26-01-2018
Risalah maklumat Risalah maklumat Lithuania 10-01-2023
Ciri produk Ciri produk Lithuania 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 26-01-2018
Risalah maklumat Risalah maklumat Hungary 10-01-2023
Ciri produk Ciri produk Hungary 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 26-01-2018
Risalah maklumat Risalah maklumat Malta 10-01-2023
Ciri produk Ciri produk Malta 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 26-01-2018
Risalah maklumat Risalah maklumat Belanda 10-01-2023
Ciri produk Ciri produk Belanda 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 26-01-2018
Risalah maklumat Risalah maklumat Poland 10-01-2023
Ciri produk Ciri produk Poland 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 26-01-2018
Risalah maklumat Risalah maklumat Portugis 10-01-2023
Ciri produk Ciri produk Portugis 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 26-01-2018
Risalah maklumat Risalah maklumat Romania 10-01-2023
Ciri produk Ciri produk Romania 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 26-01-2018
Risalah maklumat Risalah maklumat Slovak 10-01-2023
Ciri produk Ciri produk Slovak 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 26-01-2018
Risalah maklumat Risalah maklumat Slovenia 10-01-2023
Ciri produk Ciri produk Slovenia 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 26-01-2018
Risalah maklumat Risalah maklumat Finland 10-01-2023
Ciri produk Ciri produk Finland 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 26-01-2018
Risalah maklumat Risalah maklumat Sweden 10-01-2023
Ciri produk Ciri produk Sweden 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 26-01-2018
Risalah maklumat Risalah maklumat Norway 10-01-2023
Ciri produk Ciri produk Norway 10-01-2023
Risalah maklumat Risalah maklumat Iceland 10-01-2023
Ciri produk Ciri produk Iceland 10-01-2023
Risalah maklumat Risalah maklumat Croat 10-01-2023
Ciri produk Ciri produk Croat 10-01-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 26-01-2018

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen